Monoclonal Antibodies Production Platforms: An Opportunity Study of a Non-Protein-A Chromatographic Platform Based on Process Economics.

Monoclonal antibodies currently dominate the biopharmaceutical market with growing sales having reached 80 billion USD in 2016. As most top-selling mAbs are approaching the end of their patent life, biopharmaceutical companies compete fiercely in the biosimilars market. These two factors present a strong motivation for alternative process strategies and process optimization. In this work a novel purification strategy for monoclonal antibodies comprising phenylboronic acid multimodal chromatography for capture followed by polishing by ion-exchange monolithic chromatography and packed bed hydrophobic interaction chromatography is presented and compared to the traditional protein-A-based process. Although the capital investment is similar for both processes, the operation cost is 20% lower for the novel strategy. This study shows that the new process is worthwhile investing in and could present a viable alternative to the platform process used by most industrial players.

[1]  Brian D. Kelley,et al.  DOWNSTREAM PROCESSING OF MONOCLONAL ANTIBODIES: CURRENT PRACTICES AND FUTURE OPPORTUNITIES , 2008 .

[2]  Cheng Zhang,et al.  Caprylic acid precipitation method for impurity reduction: An alternative to conventional chromatography for monoclonal antibody purification , 2012, Biotechnology and bioengineering.

[3]  A. Zydney,et al.  Protein a chromatography at high titers , 2013, Biotechnology and bioengineering.

[4]  Suzanne S. Farid PhD Senior,et al.  Chapter 12. Process Economic Drivers in Industrial Monoclonal Antibody Manufacture , 2008 .

[5]  Gerhard Schembecker,et al.  Cost evaluation of antibody production processes in different operation modes , 2016 .

[6]  Mohamed Al-Rubeai,et al.  Bioreactor Systems for Producing Antibody from Mammalian Cells , 2011 .

[7]  Ruben R G Soares,et al.  Partitioning in aqueous two‐phase systems: Analysis of strengths, weaknesses, opportunities and threats , 2015, Biotechnology journal.

[8]  P A Marichal-Gallardo,et al.  State‐of‐the‐art in downstream processing of monoclonal antibodies: Process trends in design and validation , 2012, Biotechnology progress.

[9]  M. Mateus,et al.  Polishing of monoclonal antibodies streams through convective flow devices , 2014 .

[10]  R. Bayer,et al.  Recovery and purification process development for monoclonal antibody production , 2010, mAbs.

[11]  A. Hewig,et al.  Recovery and Purification of Antibody , 2011 .

[12]  Brian Kelley,et al.  Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.

[13]  Jochen Strube,et al.  Challenges in biotechnology production—generic processes and process optimization for monoclonal antibodies , 2005 .

[14]  J. Curling,et al.  The Development of Antibody Purification Technologies , 2008 .

[15]  Ana M Azevedo,et al.  Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. , 2009, Trends in biotechnology.

[16]  M. Aires-Barros,et al.  Phenylboronic acid chromatography provides a rapid, reproducible and easy scalable multimodal process for the capture of monoclonal antibodies , 2016 .

[17]  Massimo Morbidelli,et al.  Continuous counter‐current chromatography for capture and polishing steps in biopharmaceutical production , 2016, Biotechnology journal.

[18]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.

[19]  Suzanne S Farid,et al.  Established bioprocesses for producing antibodies as a basis for future planning. , 2006, Advances in biochemical engineering/biotechnology.

[20]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[21]  Suzanne S Farid,et al.  Fed‐batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty , 2013, Biotechnology and bioengineering.

[22]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[23]  Pablo A Scolnik,et al.  mAbs: a business perspective. , 2009, mAbs.

[24]  D. S. Hage,et al.  Affinity monolith chromatography: a review of principles and recent analytical applications , 2013, Analytical and Bioanalytical Chemistry.

[25]  Telma Barroso,et al.  Functional monolithic platforms: Chromatographic tools for antibody purification , 2013, Biotechnology journal.

[26]  Andrew L. Zydney,et al.  Perspectives on integrated continuous bioprocessing — opportunities and challenges , 2015 .

[27]  Ana M Azevedo,et al.  Phenylboronic acid as a multi-modal ligand for the capture of monoclonal antibodies: development and optimization of a washing step. , 2014, Journal of chromatography. A.

[28]  Günter Jagschies.  Bright Future Outlook and Huge Challenges to Overcome: An Attempt to Write the Short Story of the Biopharma Industry with Current Status, Selected Issues, and Potential Solutions in Discovery, R&D, and Manufacturing , 2013 .

[29]  Brian Kelley,et al.  Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations , 2007, Biotechnology progress.

[30]  P. Gagnon.  Technology trends in antibody purification. , 2012, Journal of chromatography. A.